Clinical Trial: Real-World Lenvatinib Sequencing in Unresectable Hepatocellular Carcinoma (uHCC)

U.S., Oct. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07849660) titled 'Real-World Lenvatinib Sequencing in Unresectable Hepatocellular Carcinoma (uHCC)' on Sept. 24.

Brief Summary: This observational study will use existing real-world data from routine clinical care to describe patients with uHCC who received lenvatinib. The study will include two groups: patients who started lenvatinib as first-line (1L) treatment and patients who started lenvatinib as second-line (2L) treatment after prior 1L immunotherapy was stopped because the cancer progressed or because of toxicity. All study information will be collected retrospectively from existing patient records. Patients will be followed from the start of l...